Hemington Wealth Management Raises Position in Johnson & Johnson (NYSE:JNJ)

Hemington Wealth Management lifted its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 1.1% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 18,604 shares of the company’s stock after acquiring an additional 196 shares during the quarter. Johnson & Johnson comprises approximately 1.3% of Hemington Wealth Management’s portfolio, making the stock its 15th largest position. Hemington Wealth Management’s holdings in Johnson & Johnson were worth $3,039,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. DORCHESTER WEALTH MANAGEMENT Co raised its stake in Johnson & Johnson by 8.6% during the first quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company’s stock valued at $14,975,000 after buying an additional 5,327 shares in the last quarter. Cantor Fitzgerald Investment Advisor L.P raised its position in shares of Johnson & Johnson by 88.9% during the 1st quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company’s stock worth $31,049,000 after purchasing an additional 82,429 shares during the period. AMI Investment Management Inc. raised its position in shares of Johnson & Johnson by 8.8% during the 1st quarter. AMI Investment Management Inc. now owns 18,305 shares of the company’s stock worth $3,244,000 after purchasing an additional 1,475 shares during the period. Equitable Holdings Inc. raised its position in shares of Johnson & Johnson by 4.9% during the 1st quarter. Equitable Holdings Inc. now owns 45,673 shares of the company’s stock worth $8,095,000 after purchasing an additional 2,119 shares during the period. Finally, USS Investment Management Ltd raised its position in shares of Johnson & Johnson by 2.4% during the 1st quarter. USS Investment Management Ltd now owns 860,371 shares of the company’s stock worth $152,488,000 after purchasing an additional 20,528 shares during the period. Hedge funds and other institutional investors own 67.94% of the company’s stock.

Analyst Ratings Changes

Several analysts recently commented on JNJ shares. Atlantic Securities lowered their target price on Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 19th. Bank of America decreased their price target on Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating for the company in a research note on Friday, October 14th. Citigroup increased their price target on Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a research note on Monday, December 12th. StockNews.com began coverage on Johnson & Johnson in a research note on Wednesday, October 12th. They set a “strong-buy” rating for the company. Finally, Credit Suisse Group initiated coverage on Johnson & Johnson in a research note on Thursday, November 17th. They set a “neutral” rating and a $170.00 price target for the company. Seven research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $181.75.

Insider Activity

In other news, CFO Joseph J. Wolk sold 14,781 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total value of $2,654,667.60. Following the completion of the transaction, the chief financial officer now owns 35,812 shares in the company, valued at $6,431,835.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CFO Joseph J. Wolk sold 14,781 shares of the business’s stock in a transaction that occurred on Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total value of $2,654,667.60. Following the completion of the transaction, the chief financial officer now owns 35,812 shares in the company, valued at approximately $6,431,835.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider William Hait sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, October 24th. The stock was sold at an average price of $171.55, for a total transaction of $2,573,250.00. Following the completion of the transaction, the insider now owns 80,236 shares of the company’s stock, valued at approximately $13,764,485.80. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 277,886 shares of company stock worth $48,550,549. Insiders own 0.35% of the company’s stock.

Johnson & Johnson Stock Down 0.5 %

NYSE JNJ opened at $168.74 on Friday. Johnson & Johnson has a 1-year low of $155.72 and a 1-year high of $186.69. The stock’s 50 day moving average is $176.14 and its two-hundred day moving average is $171.25. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37. The company has a market capitalization of $441.17 billion, a price-to-earnings ratio of 23.50, a PEG ratio of 3.28 and a beta of 0.56.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st will be paid a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.68%. The ex-dividend date of this dividend is Friday, February 17th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 62.95%.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.